Search

A recent report from researchers at the University of Wurzburg in Germany explores the role of acid ceramidase (Ac) in immune responses, specifically anti-viral immunity. The study utilized a tamoxifen-inducible global knockout mouse model to investigate the impact of Ac expression on various leukocyte populations. The findings suggest that Ac plays a crucial role in maintaining B-cell numbers and reducing IFNg secretion by CD4+ T cells. This research provides valuable insights into the potential therapeutic applications of Ac inhibitors in cancer treatment. [Extracted from the article]

A recent study conducted at the University of Texas Health Science Center in San Antonio explored the effects of rapamycin treatment on age-related changes in the liver proteome profile of a non-human primate model, the common marmoset. The researchers found that the liver proteome of old marmosets treated with rapamycin differed from that of young untreated marmosets or old untreated marmosets. Specifically, rapamycin treatment increased levels of the enzyme ceramidase, which is involved in the breakdown of ceramides. Ceramides have been linked to the development of non-alcoholic fatty liver disease (NAFLD). The study also identified changes in other proteins related to NAFLD. Further analysis is being conducted to better understand the pathways involved in age-associated hepatic fat accumulation. The research was supported by grants from the National Institute on Aging. [Extracted from the article]

Researchers from Shandong University of Traditional Chinese Medicine have conducted a study on the relationship between lipid-lowering drugs (LLDs) and lung cancer risk. Using genetic instrumental variables, the study found that inhibiting certain proteins and enzymes associated with LLDs can decrease the risk of lung cancer, particularly in ever-smokers. The study also highlighted the role of sphingolipid metabolism, specifically neutral ceramidase, in mediating the reduced lung cancer risk. These findings emphasize the complex nature of the relationship between LLDs, sphingolipid metabolites, and lung cancer risk. [Extracted from the article]

Keywords: Milwaukee; State:Wisconsin; United States; North and Central America; Life Science; Ceramidases; Enzymes and Coenzymes; Health and Medicine; Pharmacokinetics; Pharmacology EN Milwaukee State:Wisconsin United States North and Central America Life Science Ceramidases Enzymes and Coenzymes Health and Medicine Pharmacokinetics Pharmacology 967 967 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Life Science. Keywords for this news article include: Milwaukee, Wisconsin, United States, North and Central America, Life Science, Ceramidases, Enzymes and Coenzymes, Health and Medicine, Pharmacokinetics, Pharmacology, University of Wisconsin. [Extracted from the article]

The modified non-human cell of claim 1, wherein the cell exhibits no detectable ceramidase activity prior to introduction of the one or more nucleic acids encoding a human ceramidase. A modified non-human cell deficient in the expression of one or more endogenous ceramidase genes and comprising one or more nucleic acids encoding a human ceramidase. Currently, there are five known human ceramidases: acid ceramidase (AC), neutral ceramidase, alkaline ceramidase 1, alkaline ceramidase 2, and alkaline ceramidase 3. The modified non-human cell of claim 1, wherein the reduced expression of the one or more endogenous ceramidase genes is obtained by deletion of all or part of the ceramidase gene, siRNA or oligonucleotide targeting the endogenous ceramidase gene, an inducible knockout system, or CRSIPR-CAS9. [Extracted from the article]

Keywords for this news article include: Cincinnati, Ohio, United States, North and Central America, Acid Ceramidase, Amidohydrolases, Antibiotics, Ceramidases, Drugs and Therapies, Enzymes and Coenzymes, Genetic Diseases and Conditions, Health and Medicine, Hydrolases, Malformations of Cortical Development, Nervous System Diseases and Conditions, Nervous System Heredodegenerative Disorders, Nervous System Malformations, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurology, Pharmaceuticals, Rapamycin Therapy, Tuberous Sclerosis, University of Cincinnati. Keywords: Cincinnati; State:Ohio; United States; North and Central America; Acid Ceramidase; Amidohydrolases; Antibiotics; Ceramidases; Drugs and Therapies; Enzymes and Coenzymes; Genetic Diseases and Conditions; Health and Medicine; Hydrolases; Malformations of Cortical Development; Nervous System Diseases and Conditions; Nervous System Heredodegenerative Disorders; Nervous System Malformations; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurology; Pharmaceuticals; Rapamycin Therapy; Tuberous Sclerosis EN Cincinnati State:Ohio United States North and Central America Acid Ceramidase Amidohydrolases Antibiotics Ceramidases Drugs and Therapies Enzymes and Coenzymes Genetic Diseases and Conditions Health and Medicine Hydrolases Malformations of Cortical Development Nervous System Diseases and Conditions Nervous System Heredodegenerative Disorders Nervous System Malformations Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurology Pharmaceuticals Rapamycin Therapy Tuberous Sclerosis 2013 2013 1 06/26/23 20230627 NES 230627 2023 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Genetic Diseases and Conditions - Tuberous Sclerosis are discussed in a new report. [Extracted from the article]

Acid Ceramidase, Amidohydrolases, Ceramidases, Drugs and Therapies, Enzymes and Coenzymes, Health and Medicine, Hydrolases, Therapeutics, Therapy Keywords: Acid Ceramidase; Amidohydrolases; Ceramidases; Drugs and Therapies; Enzymes and Coenzymes; Health and Medicine; Hydrolases; Therapeutics; Therapy EN Acid Ceramidase Amidohydrolases Ceramidases Drugs and Therapies Enzymes and Coenzymes Health and Medicine Hydrolases Therapeutics Therapy 594 594 1 03/24/23 20230224 NES 230224 2023 FEB 24 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in drugs and therapies. [Extracted from the article]